S
Septerna, Inc. (SEPN)
NGM – Real Time Price. Currency in USD
24.84
+1.27 (5.39%)
At close: May 12, 2026, 4:00 PM EDT
25.14
+0.30 (1.21%)
After-hours: May 12, 2026, 6:33 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
24.84
+1.27 (5.39%)
At close: May 12, 2026, 4:00 PM EDT
25.14
+0.30 (1.21%)
After-hours: May 12, 2026, 6:33 PM EDT
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
| Name | Position |
|---|---|
| Dr. Arthur Christopoulos BPHARM, Ph.D. | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board |
| Dr. Jeffrey T. Finer M.D., Ph.D. | Co-Founder, CEO & Director |
| Dr. Patrick Sexton Ph.D. | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board |
| Dr. Robert J. Lefkowitz M.D. | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board |
| Mr. George Xu Ph.D. | Senior Director of Corporate Development & Portfolio Strategy |
| Mr. Gilbert M. Labrucherie C.F.A., J.D. | Chief Financial Officer |
| Mr. Mark A. Wilson J.D. | Chief Legal Officer |
| Mr. Richard Hansen Ph.D. | Vice President of Technology |
| Ms. Elizabeth P. Bhatt M.B.A., M.S. | President & COO |
| Ms. Samira Shaikhly | Chief People Officer |
| Date | Type | Document |
|---|---|---|
| 2026-04-30 | DEF 14A | sepn-20260430.htm |
| 2026-04-13 | 8-K | d57504d8k.htm |
| 2026-03-10 | S-3ASR | d25619ds3asr.htm |
| 2026-03-09 | S-8 | d929650ds8.htm |
| 2026-03-02 | 8-K | d44190d8k.htm |
| 2026-01-12 | 8-K | d81130d8k.htm |
| 2026-01-08 | 8-K | d40604d8k.htm |
| 2025-11-10 | 10-Q | sepn-20250930.htm |
| 2025-09-29 | 8-K | d942032d8k.htm |
| 2025-09-03 | 8-K | d946079d8k.htm |